Research programme: cancer therapeutics - Molecular Templates

Drug Profile

Research programme: cancer therapeutics - Molecular Templates

Alternative Names: 3F7; 5G2; MT 2289; MT 4019; MT 5111; MT 6868; MT-2274; MT-6035; MT-SAM3; TAK 169

Latest Information Update: 03 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Templates
  • Developer Eli Lilly; Enzon Pharmaceuticals; Molecular Templates
  • Class Antibodies; Antineoplastics; Bacterial toxins; Drug conjugates; Recombinant proteins; Small interfering RNA
  • Mechanism of Action CD38 antigen inhibitors; ERBB 2 receptor antagonists; Immunostimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Malignant melanoma; Multiple myeloma
  • Research Cancer; Hodgkin's disease

Most Recent Events

  • 14 May 2018 Molecular Templates intends to submit an IND application to the US FDA for a phase I trial of MT 4019 in Multiple myeloma in the third quarter of 2018
  • 14 May 2018 Molecular Templates plans a phase I trial of MT 4019 for Multiple myeloma in USA in the second half of 2018
  • 28 Mar 2018 MT 5050 is still in preclinical trials for Melanoma in USA (Molecular templates pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top